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relief system of the Pharmaceuticals and Medical Devices AgencyTable 1
Summary of ADR cases due to LTG.
Eligible
cases
Ineligible
cases
Assessed
cases
Fiscal years 2009 2 0 2
2010 7 1 8
2011 6 3 9
2012 45 41 86
2013 40 26 66
2014 49 24 73
2015 46 22 68
Total 195 117 312
Gender Male 61 31 92 (29.5%)
Female 134 86 220 (70.5%)
Total 195 117 312 (100.0%)
Ages 0e9 2 0 2 (0.6%)
10e19 7 6 13 (4.2%)
20e29 36 16 52 (16.7%)
30e39 56 38 94 (30.1%)
40e49 41 24 65 (20.8%)
50e59 26 17 43 (13.8%)
60e69 18 8 26 (8.3%)
70e79 8 7 15 (4.8%)
80e 1 1 2 (0.6%)
Total 195 117 312 (100.0%)
Drug eruptions EM 61 (31.6%) 40 (34.5%) 101 (32.7%)
DIHS 65 (33.7%) 27 (23.2%) 92 (29.8%)
MP 21 (10.9%) 21 (18.1%) 42 (13.6%)
SJS 19 (9.8%) 13 (11.2%) 32 (10.4%)
TEN 11 (5.7%) 9 (7.8%) 20 (6.5%)
Others 16 (8.3%) 6 (5.2%) 22 (7.1%)
Total 193 (100.0%) 116 (100.0%) 309 (100.0%)Dear Editor,
Lamotrigine (LTG) is one of the newer antiepileptic drugs (AED)
and is also effective for the treatment of bipolar disorder. In Japan,
LTG was ﬁrst approved as add-on therapy for patients with recalci-
trant epilepsy in 2008. It was approved for the suppression of recur-
rent/relapsed mood episodes in patients with bipolar disorder in
2011, and was also approved for monotherapy in epileptic patients
in 2014. The primary safety concern with LTG is drug eruptions,
with benign eruptions occurring in about 10% of patients and
serious eruptions in about 0.1%.1 The incidence of drug eruptions
is well recognized to be dose- and titration-dependent, and is
related to concomitant use of valproic acid (VPA).2 Slow titration
of LTG is known to markedly reduce the incidence of serious drug
eruptions.3 Japan has a relief system for sufferers from adverse
drug reactions (ADRs) managed by the Pharmaceuticals and Medi-
cal Devices Agency (PMDA).4 This system provides relief beneﬁts
for patients with diseases that require hospitalization caused by
ADRs in the appropriate use of the drugs concerned. In recent years
the number of cases with ADRs due to LTG assessed to determine
whether or not the patients are eligible for relief beneﬁts has
increased.5 We analyzed the open data on ADRs due to LTG
(http://www.pmda.go.jp/relief-services/index.html) and eluci-
dated the recent trend of these ADRs. The c2-test was used to
analyze the data, and p values of less than 0.05 were considered
statistically signiﬁcant.
Table 1 shows a summary of ADR cases due to LTG. The ﬁrst two
cases were reported in ﬁscal year (FY) 2009 and a total of 312 cases
have been reported as of FY 2015. Figure 1(a) depicts the number of
cases assessed from FY 2009 to 2015. The numbers in FY 2010 and
2011 were 8 and 9, respectively. In FY 2012, the number dramati-
cally increased to 86, and thereafter slightly decreased to around
70, with 66, 73 and 68 cases in FY 2013, 2014 and 2015, respec-
tively. Figure 1(b) shows the percentages of ineligible cases among
the total numbers of cases assessed from FY 2009 to 2015. The per-
centage was 0% in FY 2009, but it increased until FY 2012, with
12.5%, 33.3% and 47.7% being ineligible in FY 2010, 2011 and
2012, respectively. Thereafter, it gradually decreased to around
one-third, being 39.3%, 32.8% and 32.3% in FY 2013, 2014 and
2015, respectively. Of the 117 ineligible cases, 106 (90.6%) were
judged to be so because of non-compliance with dosage and
administration. Of the total of 312 patients, 92 (29.5%) were males
and 220 (70.5%) were females (Table 1). Of the 312 patients, 6Peer review under responsibility of Japanese Society of Allergology.
http://dx.doi.org/10.1016/j.alit.2016.07.006
1323-8930/Copyright © 2016, Japanese Society of Allergology. Production and hosting by Else
licenses/by-nc-nd/4.0/).(1.9%) died because of ADRs due to LTG, with 5 and 1 cases
receiving and not receiving relief beneﬁts, respectively. Of the
312 cases, LTG was the only causal drug in 228 (73.1%), whereas
the other 84 (26.9%) included other causal drugs, and 19 cases
(6.1%) included VPA as another causal drug. Of the 312 cases, 309
(99.0%) were drug eruptions, of which the most frequent type
was erythema multiforme (32.7%), followed by drug-induced hy-
persensitivity syndrome (DIHS: 29.8%), the maculopapular type
(13.6%), StevenseJohnson syndrome (SJS: 10.4%) and toxic
epidermal necrolysis (TEN: 6.5%, Table 1). Of the 6 fatal cases, 4
were males and 2 were females. Two cases were 80 years or older,
1 between 0 and 9, 1 between 40 and 49, 1 between 50 and 59, and
1 between 60 and 69. One case included VPA as another causal
drug. Four cases were DIHS, 1 SJS, and 1 TEN.ADR, adverse drug eruption; LTG, lamotrigine; EM, erythema multiforme; DIHS,
drug-induced hypersensitivity syndrome; MP, maculopapular type; SJS, Stevens-
Johnson syndrome; TEN, toxic epidermal necrolysis.
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Fig. 1. (a) Number of assessed cases with adverse drug reactions (ADR) due to lamotrigine (LTG) from ﬁscal year (FY) 2009e2015. (b) Percentages of ineligible to assessed cases with
ADR due to LTG from FY 2009 to 2015.
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and the ﬁrst ADR case due to LTG in the relief system was reported
in FY 2009. The number of total cases assessed dramatically
increased in FY 2012, probably because LTG was additionally
approved for patients with bipolar disorder in 2011. Furthermore,
the ratio of ineligible to total cases increased until FY 2012, and
most of the ineligible cases were judged to be so because of non-
compliance with the dosage and administration regimen. LTG
must be administered with an initial dose of 25 mg/day for two
weeks, followed by 50 mg/day for the next two weeks. Especially
in presence of VPA, the initial dose must be 25 mg on alternate
days for two weeks, followed by 25 mg/day for the next twoweeks.
In 2012, the PMDA sent an alert for proper use of LTG emphasizing
compliance with the dosage and administration protocol and to
ensure early detection of serious LTG-induced skin disorders
(http://www.info.pmda.go.jp/iyaku_info/tekisei_pmda_06.pdf).
Probably because of the alert, the ratio of ineligible to total cases
has gradually decreased since FT 2013, but about one-third of cases
were not eligible for relief beneﬁts in FY 2015. In 2015, the Ministry
of Health, Labour and Welfare of Japan sent the same kind of alert
about the proper use of LTG, and it is expected that the ratio of inel-
igible to total cases will further decrease from FY 2016. About 70% of
the patients were females, consistent with the observation by
Wang et al. that there were higher rates of AED-related skin reac-
tions in females than in males.2 They also disclosed that skin reac-
tions were reported three times as frequently with aromatic AED
including LTG than with non-aromatic AED.2 Based on the 6 fatal
cases of this study, it seemed that the risk factors for fatality in
ADRs due to LTG were gender (male), ages (younger than 10, and
80 or older) and drug eruption types (DIHS and SJS/TEN), although
other large studies will be necessary.
In summary, there have been many reports of ADRs due to LTG
from the relief system in the past four years and one-third of thecases were not eligible for relief beneﬁts in the last two years
because of non-compliance with the dose and administration pro-
tocol. Psychiatrists, neurosurgeons and pediatricians should strictly
comply with the guidelines for the proper use of LTG and allergol-
ogists should endeavor to ensure the early detection of severe LTG-
induced skin eruptions.5Conﬂict of interest
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